Supernus Pharmaceuticals | SUPN - Interest Expense On Debt


Supernus Pharmaceuticals reported $910K in Interest Expense on Debt for its fiscal quarter ending in June of 2023.





Interest Expense On Debt Change Date
Abbott USD 42M 2M Dec/2025
ANI Pharmaceuticals USD 4.73M 711K Sep/2025
Aurora Cannabis CAD 2.22M 442K Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Canopy Growth CAD 8.8M 938K Sep/2025
Cara Therapeutics 43.75M 4.8M Jun/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Eisai JPY 1.43B 12M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Pacira USD 4.28M 456K Sep/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
United Therapeutics USD 3M 4.3M Sep/2025
Xeris Pharmaceuticals USD 7.27M 92K Sep/2025